Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: A systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{03980e7240d4449c81bd18b1ad5428ba,
title = "Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: A systematic review",
abstract = "Cognitive impairments are a core feature of several neuropsychiatric disorders. A common biomarker for pro-cognitive effects may provide a much-needed tool to select amongst candidate treatments targeting cognition. The hippocampus is a promising biomarker for target-engagement due to the illness-associated morphological hippocampal changes across unipolar disorder (UD), bipolar disorder (BD) and schizophrenia (SCZ). Following the PRISMA guidelines, we searched PubMed and Embase, for clinical trials targeting cognition across neuropsychiatric disorders, with longitudinal structural magnetic resonance imaging (MRI) measures of the hippocampus. Five randomized and three open-label trials were included. Hippocampal volume increases were associated with treatment-related cognitive improvement following treatment with erythropoietin across UD, BD and SCZ, lithium treatment in BD and aerobic exercise in SCZ. Conversely, an exercise intervention in UD showed no effect on hippocampal volume or cognition. Together, these observations point to hippocampal volume change as a putative biomarker-model for cognitive improvement. Future cognition trials are encouraged to include MRI assessments pre- and post-treatment to assess the validity of hippocampal changes as a biomarker for pro-cognitive effects.",
keywords = "Cognition Disorders/etiology, Hippocampus/diagnostic imaging, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging/methods, Mental Disorders/complications, Treatment Outcome, Biomarker, Schizophrenia, Bipolar disorder, Unipolar disorder, Neuropsychiatric disorders, Hippocampus",
author = "Ott, {Caroline Vintergaard} and Johnson, {Claire Bergstrom} and Julian Macoveanu and Kamilla Miskowiak",
note = "Copyright {\textcopyright} 2019 Elsevier B.V. and ECNP. All rights reserved.",
year = "2019",
month = mar,
day = "1",
doi = "10.1016/j.euroneuro.2019.01.105",
language = "English",
volume = "29",
pages = "319--329",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier BV",
number = "3",

}

RIS

TY - JOUR

T1 - Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders

T2 - A systematic review

AU - Ott, Caroline Vintergaard

AU - Johnson, Claire Bergstrom

AU - Macoveanu, Julian

AU - Miskowiak, Kamilla

N1 - Copyright © 2019 Elsevier B.V. and ECNP. All rights reserved.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Cognitive impairments are a core feature of several neuropsychiatric disorders. A common biomarker for pro-cognitive effects may provide a much-needed tool to select amongst candidate treatments targeting cognition. The hippocampus is a promising biomarker for target-engagement due to the illness-associated morphological hippocampal changes across unipolar disorder (UD), bipolar disorder (BD) and schizophrenia (SCZ). Following the PRISMA guidelines, we searched PubMed and Embase, for clinical trials targeting cognition across neuropsychiatric disorders, with longitudinal structural magnetic resonance imaging (MRI) measures of the hippocampus. Five randomized and three open-label trials were included. Hippocampal volume increases were associated with treatment-related cognitive improvement following treatment with erythropoietin across UD, BD and SCZ, lithium treatment in BD and aerobic exercise in SCZ. Conversely, an exercise intervention in UD showed no effect on hippocampal volume or cognition. Together, these observations point to hippocampal volume change as a putative biomarker-model for cognitive improvement. Future cognition trials are encouraged to include MRI assessments pre- and post-treatment to assess the validity of hippocampal changes as a biomarker for pro-cognitive effects.

AB - Cognitive impairments are a core feature of several neuropsychiatric disorders. A common biomarker for pro-cognitive effects may provide a much-needed tool to select amongst candidate treatments targeting cognition. The hippocampus is a promising biomarker for target-engagement due to the illness-associated morphological hippocampal changes across unipolar disorder (UD), bipolar disorder (BD) and schizophrenia (SCZ). Following the PRISMA guidelines, we searched PubMed and Embase, for clinical trials targeting cognition across neuropsychiatric disorders, with longitudinal structural magnetic resonance imaging (MRI) measures of the hippocampus. Five randomized and three open-label trials were included. Hippocampal volume increases were associated with treatment-related cognitive improvement following treatment with erythropoietin across UD, BD and SCZ, lithium treatment in BD and aerobic exercise in SCZ. Conversely, an exercise intervention in UD showed no effect on hippocampal volume or cognition. Together, these observations point to hippocampal volume change as a putative biomarker-model for cognitive improvement. Future cognition trials are encouraged to include MRI assessments pre- and post-treatment to assess the validity of hippocampal changes as a biomarker for pro-cognitive effects.

KW - Cognition Disorders/etiology

KW - Hippocampus/diagnostic imaging

KW - Humans

KW - Image Processing, Computer-Assisted

KW - Magnetic Resonance Imaging/methods

KW - Mental Disorders/complications

KW - Treatment Outcome

KW - Biomarker

KW - Schizophrenia

KW - Bipolar disorder

KW - Unipolar disorder

KW - Neuropsychiatric disorders

KW - Hippocampus

UR - http://www.scopus.com/inward/record.url?scp=85059868483&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2019.01.105

DO - 10.1016/j.euroneuro.2019.01.105

M3 - Review

C2 - 30654916

VL - 29

SP - 319

EP - 329

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 3

ER -

ID: 58079738